OnCusp Therapeutics

formerly OnCusp

We deliver hope to cancer patients worldwide.

OnCusp Therapeutics is a biotech company in Princeton, United States, founded in 2021. It has raised $125.0M across 2 rounds, most recently a $100.0M Series A in January 2024.

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$125.0M
Last Round
$100.0M Series AJan 2024
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 7 investors for this company. to use credits for reveals, or explore the API.

About

OnCusp Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class oncology therapies, including antibody-drug conjugates (ADCs) and other targeted cancer treatments. Co-founded in 2021 by veterans from Merck, Novartis, and Daiichi Sankyo, the company advanced its lead asset CUSP06 — a CDH6-targeted ADC — into Phase 1 clinical trials and has raised $139M from investors including Novo Holdings and OrbiMed.

Funding History

Data from Indexed.vcUpdated
Series ASeries AJan 2024
$100.0M

1 more funding event

  • Seed20214 investors

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Backend ×1
  • Cloud/Infrastructure ×1
  • Frontend ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech
Corporate RoundTotal funding$1.0BApr 2020
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech
Private EquityTotal funding$3.9BJan 2019

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

OnCusp Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/oncusp-therapeutics"><img src="https://indexed.vc/api/badge/company/oncusp-therapeutics" alt="OnCusp Therapeutics on Indexed.vc" width="260" height="76" /></a>